Clearmind starts Phase IIa dosing in alcohol use disorder trial, six patients enrolled

Clearmind Medicine Inc. announced on September 1, 2026 that it has begun Phase IIa of its ongoing clinical trial of CMND-100 for alcohol use disorder (AUD), reporting that six patients have been enrolled to date in this next stage of the double-blind, placebo-controlled Phase I/IIa study, described in the release headline as one-third of Part C enrolled.¹ The release does not specify the total planned enrollment for Part C, so the fraction cannot be independently verified from the document.

Three participants were enrolled at Tel Aviv Sourasky Medical Center and three at Hadassah Medical Center in Jerusalem, marking the start of the first multiple-dose treatment phase of Part C, following completion of the trial's initial safety portion in healthy volunteers.¹

The Phase IIa trial is intended to assess safety, tolerability and preliminary efficacy of CMND-100 in people with moderate-to-severe AUD, as part of a four-part Phase I/IIa study examining single and multiple dose tolerability, safety and pharmacokinetics in both healthy volunteers and AUD patients.¹

Clearmind said an independent Data and Safety Monitoring Board had reviewed data from Part A of the trial and recommended proceeding to subsequent parts, supporting continued evaluation of CMND-100 along with simultaneous progression into multiple dosing in healthy volunteers and single dosing in the AUD patient group.¹

CMND-100 is described as Clearmind's lead investigational psychedelic-based therapeutic candidate being developed as a potential treatment for AUD.¹ The company also noted its intellectual property portfolio includes nineteen patent families and 32 granted patents.¹